



## Erratum

**Burnett AE, Ragheb B, Kaatz S. Perioperative consultative hematology: can you clear my patient for a procedure? *Hematology Am Soc Hematol Educ Program.* 2021;2021:521-528.**

Page 521: In the first bullet point under "Introduction," "must to be made" should read "must be made."

Page 523: In the sentence that begins "In addition" in the first paragraph, "little to no residual anticoagulant effect from more than 30 ng/mL" should read "little to no residual anticoagulant effect of more than 30 ng/mL."

Page 523: In the second column from the right in Table 2, the heading "Dabigatran CrCl <0" should read "Dabigatran CrCl <50."

Page 523: In the first sentence of the second paragraph under "Warfarin," "foregoing" should read "forgoing."

Page 524: In the first bullet point under "Thromboembolic risk stratification," "CHADS<sub>2</sub>-VA<sub>2</sub>Sc" should read "CHA<sub>2</sub>DS<sub>2</sub>-VASc."

Page 524: In Table 3, in the "Atrial fibrillation" section and the footnote, "CHA<sub>2</sub>DS-VA<sub>2</sub>Sc" should read "CHA<sub>2</sub>DS<sub>2</sub>-VASc."

Page 526: In the second paragraph under "Off-label drug use," "Bishoy Raghe" should read "Bishoy Ragheb."

The errors have been corrected in the published article.

---

DOI 10.1182/hematology.2022E01